Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update
November 04, 2021 16:05 ET | Bellicum Pharmaceuticals, Inc.
- Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology - - Charity Scripture, MS, PharmD, appointed Chief...
Official_Bellicum_Logo_RGB.jpg
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 03, 2021 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick...
Official_Bellicum_Logo_RGB.jpg
Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch
September 01, 2021 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, and The University of Texas...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Second Quarter 2021 Financial Results and Provides Operational Update
August 12, 2021 16:05 ET | Bellicum Pharmaceuticals, Inc.
- Entered into a licensing agreement with two leading oncology research and treatment centers for use of CaspaCIDe® safety switch technology - - Enrollment continuing in Phase 1/2 dose-escalation...
Official_Bellicum_Logo_RGB.jpg
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 26, 2021 17:25 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced an equity...
Official_Bellicum_Logo_RGB.jpg
Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
March 23, 2021 16:05 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will...
Official_Bellicum_Logo_RGB.jpg
Bellicum to Participate in Two Upcoming Virtual Investor Conferences
September 02, 2020 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 31, 2020 16:07 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Official_Bellicum_Logo_RGB.jpg
Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors
June 15, 2020 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, June 15, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced clearance by...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 29, 2020 16:06 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, May 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...